Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004881 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Advanced Cancer
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00004881 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Jonsson Comprehensive Cancer Center. The trial reports 1 study location across 1 state.
The verdict
NCT00004881, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
Conditions Studied
Interventions
- BIOLOGICAL MVA-MUC1-IL2 vaccine
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-04 |
| Est. Completion | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004881
The ClinicalTrials.gov registry entry for NCT00004881 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which MVA-MUC1-IL2 vaccine is the first listed.
NCT00004881 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00004881 about?
NCT00004881 is a clinical study titled "Vaccine Therapy in Treating Patients With Advanced Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
What is the current status of trial NCT00004881?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-04. Estimated completion is 2004-05.
What conditions does trial NCT00004881 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00004881?
The interventions under investigation include: MVA-MUC1-IL2 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004881?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004881 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.